A Study to Evaluate the Safety of Empliciti® (Elotuzumab) When Treating Patients With Multiple Myeloma in Taiwan

Bristol-Myers Squibb (BMS)

Status

Enrolling

Conditions

Relapsed or Refractory Multiple Myeloma

Treatments

Drug: Elotuzumab in combination with pomalidomide and dexamethasone

Drug: Elotuzumab in combination with lenalidomide and dexamethasone

Study type

Observational

Funder types

Industry

Identifiers

NCT06163040

CA204-219

Details and patient eligibility

About

This observational study aimed to assess the safety of elotuzumab when used in combination with pomalidomide and dexamethasone for the treatment of relapsed and refractory multiple myeloma (RRMM) in participants who had received at least two prior therapies, including lenalidomide and a proteasome inhibitor. The study will also assess the safety of elotuzumab when used in combination with lenalidomide and dexamethasone in RRMM participants who had received one to three prior therapies.

Enrollment

27 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Age ≥ 18 years
Confirmed diagnosis of RRMM
Received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor
Planning to receive elotuzumab in combination with pomalidomide and dexamethasone at physician's medical judgement OR
Age ≥ 18 years
Confirmed diagnosis of RRMM
Received one to three prior therapies
Planning to receive elotuzumab in combination with lenalidomide and dexamethasone at physician's medical judgement

Exclusion criteria

Participants with therapeutic indications for which elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone has not been approved in Taiwan
Participants who are contraindicated for treated with elotuzumab in combination with pomalidomide/lenalidomide and dexamethasone (as described in the Taiwan label)
Participants who participate in other interventional clinical trials